Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Paclitaxel-coated balloon (PCB) and sirolimus-coated balloon have both been shown to be superior to plain old balloon angioplasty (POBA) in maintaining the patency of arteriovenous fistula (AVF). However, they work through different mechanisms to combat neointimal hyperplasia within the AVF circuit, and there have been no head-to-head comparisons of PCB and SCB in AVF. This real-world registry aims to compare the efficacy and safety of PCB vs SCB in the treatment of AVF stenosis.
A total of 116 patients who received PCB or SCB treatment during percutaneous angioplasty (PTA) for all the stenosis within their AVF circuits were enrolled. Propensity score matching was performed using the following baseline characteristics: age, gender, presence of diabetes, duration of end-stage kidney failure (ESKF), type of AVF, age of AVF, number of previous interventions, and use of antiplatelet and anticoagulants. The matched sample consists of 78 well-matched groups of patients (39 in the PCB and 39 in the SCB groups) that have completed at least 6 months follow-up as of 25 September 2025. The primary outcome was access circuit primary patency (ACPP) at 6 months, while the secondary outcomes were target lesion primary patency (TLPP), access circuit primary assisted patency, access circuit secondary patency at 6 and 12 months. The safety endpoint was patient survival at 6 and 12 months.
Kaplan Meier survival analysis demonstrated that the 6-month ACPP of PCB vs. SCB was 66.0% (95% CI: 52.0 – 83.8%) vs. 51.8% (95% CI: 37.1 – 72.2%), p = 0.983. The TLPP at 6 months was 77.1% (95% CI: 65.5 – 90.7%) vs. 63.2% (50.7 – 78.8%), p = 0.34. The access circuit primary-assisted patency and secondary patency at 6 months were 88.7% (95% CI: 78.8 – 99.8%) vs. 93.8% (95% CI: 85.7 – 100%), p = 0.22, and 100% vs.100%, p = 0.68, respectively. Patient survival was 89.5% (80.3 – 99.8%) vs. 94.6% (87.5 – 200%), p = 073.
The preliminary results of this study demonstrated that SCB angioplasty is a safe alternative to PCB in maintaining post-angioplasty patency. However, more patients should be enrolled and matched to reduce the possibility of type 1 error. Further large-scale randomized controlled trials are also needed to confirm the observations.
